Health
Pharmalittle FDA Rejection and Legal Battles
The FDA rejected a radiopharmaceutical therapy due to manufacturing issues, impacting competition in the market. Legal battles over the 340B drug pricing program are ongoing.
Coverage timeline — 1 article
STAT News
The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis
2026-08-11 13:27 UTC